Medlab granted a licence to export cannabis

Australian medical life sciences company Medlab Clinical has received a licence to export cannabis from the Office of Drug Control (ODC) in Canberra, as it relates to the company’s two cannabis-based medicines — NanaBis and NanaBidial.

NanaBis is a whole plant 1:1 extract of CBD and THC, while NanaBidial is a whole plant extract of CBD and THC (predominantly CBD). Both products utilise Medlab’s NanoCelle delivery platform, which allows the delivery of nanoparticles of the active pharmaceutical ingredients into the side of the cheek. This is intended to improve ease of delivery along with the speed and rate of absorption into the bloodstream, bypassing traditional routes of delivery such as the gastrointestinal/hepatic, ingested route.

Medlab recently announced preliminary results received from The University of Sydney Nano Institute, which validate the science behind the NanoCelle delivery platform. The research concluded positively that molecules of NanaBis and NanaBidial showed a consistent uniform pattern in nanoparticle form.

“These results provide a significant level of confidence in Medlab’s NanoCelle platform and further confirms specific proposed functions for Medlab’s cannabis medicines,” said Medlab CEO Dr Sean Hall. “These results, in conjunction with the early positive feedback from doctors prescribing NanaBis under the TGA’s Special Access Scheme, gives Medlab great confidence in its NanoCelle research.”

Dr Hall added that the new export licence allows Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the company can supply legally overseas. He said, “This licence is a welcome addition to our other approvals, allowing Medlab to research, manufacture, conduct research trials, supply within Australia, and now, pending the right partner, foreign markets.”

The licence is renewable annually.

Image credit: ©William Casey/Dollar Photo Club